A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 28,649 shares of SRRK stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,649
Previous 8,193 249.68%
Holding current value
$1.27 Million
Previous $68,000 236.76%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.63 - $9.71 $156,079 - $198,627
20,456 Added 249.68%
28,649 $229,000
Q2 2024

Aug 14, 2024

SELL
$7.84 - $16.79 $1.83 Million - $3.93 Million
-233,963 Reduced 96.62%
8,193 $68,000
Q1 2024

May 15, 2024

SELL
$13.2 - $17.76 $11.7 Million - $15.8 Million
-889,512 Reduced 78.6%
242,156 $4.3 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $7.38 Million - $23 Million
1,131,668 New
1,131,668 $21.3 Million
Q1 2023

May 15, 2023

BUY
$7.36 - $12.72 $113,660 - $196,434
15,443 New
15,443 $123,000
Q2 2020

Aug 14, 2020

SELL
$10.37 - $20.64 $3.56 Million - $7.09 Million
-343,333 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$9.63 - $17.14 $2.57 Million - $4.57 Million
266,869 Added 349.01%
343,333 $4.16 Million
Q4 2019

Feb 14, 2020

BUY
$7.2 - $13.2 $550,540 - $1.01 Million
76,464 New
76,464 $1.01 Million
Q2 2019

Aug 14, 2019

SELL
$14.61 - $22.45 $2.92 Million - $4.49 Million
-200,000 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$14.24 - $22.28 $2.85 Million - $4.46 Million
200,000 New
200,000 $3.76 Million
Q3 2018

Nov 14, 2018

SELL
$13.39 - $26.25 $129,883 - $254,625
-9,700 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$15.0 - $25.6 $145,500 - $248,320
9,700 New
9,700 $151,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.28B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.